OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.008004108775838263 | N/A |
Market Cap | $15.80M | N/A |
Shares Outstanding | 1.97B | 97.87% |
Employees | 0 | N/A |
Shareholder Equity | 9.88M | -11.49% |
Valuation | 2023 | Change |
---|---|---|
P/S Ratio | 64.44 | N/A |
P/B Ratio | 1.60 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.7657 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $245.24K | N/A |
Earnings | -$7.57M | N/A |
Gross Margin | -3.32 | N/A |
Operating Margin | -34.62 | N/A |
Net income margin | -30.85 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $7.65M | N/A |
Total Debt | $113.93K | N/A |
Cash on Hand | $6.34M | N/A |
Debt to Equity | 0.1076 | -5.56% |
Cash to Debt | $55.68 | 48.99% |
Current Ratio | $7.16 | -0.68% |